Gene · 64006
Papers4,423
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 4,423
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Breadth of Bacteriophages Contributing to the Development of the Phage-Based Vaccines for COVID-19: An Ideal Platform to Design the Multiplex Vaccine. | Int J Mol Sci | 2023 | 36675046 | PubTator, text mining | PubMed |
| Kaposi's Sarcoma-Associated Herpesvirus ORF21 Enhances the Phosphorylation of MEK and the Infectivity of Progeny Virus. | Int J Mol Sci | 2023 | 36674756 | PubTator, text mining | PubMed |
| Structural and Functional RNA Motifs of SARS-CoV-2 and Influenza A Virus as a Target of Viral Inhibitors. | Int J Mol Sci | 2023 | 36674746 | PubTator, text mining | PubMed |
Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2. | Biomedicines | 2023 | 36672668 | PubTator, text mining | PubMed |
| Digestive system infection by SARS‑CoV‑2: Entry mechanism, clinical symptoms and expression of major receptors (Review). | Int J Mol Med | 2023 | 36660939 | PubTator, text mining | PubMed |
| Bioinformatic analysis of the S protein of human respiratory coronavirus. | Mol Phylogenet Evol | 2023 | 36657625 | PubTator, text mining | PubMed |
| SARS-CoV-2 variant biology: immune escape, transmission and fitness. | Nat Rev Microbiol | 2023 | 36653446 | PubTator, text mining | PubMed |
| A perspective on SARS-CoV-2 virus-like particles vaccines. | Int Immunopharmacol | 2023 | 36649673 | PubTator, text mining | PubMed |
| A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19). | Antibodies (Basel) | 2023 | 36648889 | PubTator, text mining | PubMed |
| Substitution of gp120 C4 region compensates for V3 loss-of-fitness mutations in HIV-1 CRF01_AE co-receptor switching. | Emerg Microbes Infect | 2023 | 36647730 | PubTator, text mining | PubMed |
| Screening and confirmation tests for SARS-CoV-2: benefits and drawbacks. | Beni Suef Univ J Basic Appl Sci | 2023 | 36647397 | PubTator, text mining | PubMed |
| Identification of the potential matrix protein of invertebrate iridescent virus 6 (IIV6). | J Invertebr Pathol | 2023 | 36640993 | PubTator, text mining | PubMed |
| Liquid-liquid phase separation of nucleocapsid proteins during SARS-CoV-2 and HIV-1 replication. | Cell Rep | 2023 | 36640305 | PubTator, text mining | PubMed |
| Structure and neutralization mechanism of a human antibody targeting a complex Epitope on Zika virus. | PLoS Pathog | 2023 | 36626401 | PubTator, text mining | PubMed |
| HIV-1 is dependent on its immature lattice to recruit IP6 for mature capsid assembly. | Nat Struct Mol Biol | 2023 | 36624347 | PubTator, text mining | PubMed |
| A method for mapping the linear epitopes targeted by the natural antibody response to Zika virus infection using a VLP platform technology. | Virology | 2023 | 36623351 | PubTator, text mining | PubMed |
| Subunit microparticulate vaccine delivery using microneedles trigger significant SARS-spike-specific humoral and cellular responses in a preclinical murine model. | Int J Pharm | 2023 | 36610521 | PubTator, text mining | PubMed |
| A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? | Inflammopharmacology | 2023 | 36609716 | PubTator, text mining | PubMed |
| Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2. | Cell Discov | 2023 | 36609376 | PubTator, text mining | PubMed |
| SERTAD3 induces proteasomal degradation of ZIKV capsid protein and represents a therapeutic target. | J Med Virol | 2023 | 36594413 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64006/papers?page=31